Effect of locally administered Syk siRNA on allergen-induced arthritis and asthma

Molecular Immunology

Volumn 53, Issue 1-2, 2013, Pages 52-59

  Huang, Zhen Yu ^a   Kim, Moo Kyung ^a   Kim Han, Tae Hee ^a   Indik, Zena K ^a   Schreiber, Alan D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Arthritis; Pulmonary inflammation; Syk kinase; Syk siRNA

Indexed keywords

ALLERGEN; GAMMA INTERFERON; INTERLEUKIN 4; INTERLEUKIN 6; PROTEIN KINASE SYK; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ASTHMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DRUG INSTILLATION; EMBRYO; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; INFLAMMATORY CELL; JOINT; JOINT SWELLING; LUNG LAVAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RNA INTERFERENCE; SENSITIZATION;

ALLERGENS; ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; ASTHMA; BLOTTING, WESTERN; FEMALE; HUMANS; HYPERSENSITIVITY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED C57BL; PNEUMONIA; PROTEIN-TYROSINE KINASES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

MUS;

EID: 84863770986     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2012.06.011     Document Type: Article

References (51)

1. Arndt P.G., et al. Lipopolysaccharide-induced c-Jun NH2-terminal kinase activation in human neutrophils: role of phosphatidylinositol 3-kinase and Syk-mediated pathways. Journal of Biological Chemistry 2004, 279:10883-10891.
2. Barnes P.J. The cytokine network in asthma and chronic obstructive pulmonary disease. Journal of Clinical Investigation 2008, 118:3546-3556.
3. Boers M. Syk kinase inhibitors for RA: trials and tribulations. Arthritis and Rheumatism 2011, 63:329-330.
4. Braselmann S., et al. R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation. Journal of Pharmacology and Experimental Therapeutics 2006, 319:998-1008.
5. Busse W.W., Lemanske R.F. Asthma. New England Journal of Medicine 2001, 344:350-362.
6. Cha H.-S., et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. Journal of Pharmacology and Experimental Therapeutics 2006, 317:571-578.
7. Christodoulou C., Choy E.H. Joint inflammation and cytokine inhibition in rheumatoid arthritis. Clinical and Experimental Medicine 2006, 6:13-19.
8. Genovese M.C., et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis and Rheumatism 2011, 63:337-345.
9. Grünweller A., Hartmann R.K. RNA interference as a gene-specific approach for molecular medicine. Current Medicinal Chemistry 2005, 12:3143-3161.
10. Guerne P.A., et al. Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. Journal of Clinical Investigation 1989, 83:585-592.
11. Han Z., et al. Jun N-terminal kinase in rheumatoid arthritis. Journal of Pharmacology and Experimental Therapeutics 1999, 291:124-130.
12. Hartwig C., et al. Fcgamma receptor-mediated antigen uptake by lung DC contributes to allergic airway hyper-responsiveness and inflammation. European Journal of Immunology 2010, 40:1284-1295.
13. Hirano T. Revival of the autoantibody model in rheumatoid arthritis. Nature Immunology 2002, 3:342-344.
14. Houssiau F.A. Cytokines in rheumatoid arthritis. Clinical Rheumatology 1995, 14(Suppl. 2):10-13.
15. Hueber A.J., McInnes I.B. Is spleen tyrosine kinase inhibition an effective therapy for patients with RA?. Nature Clinical Practice Rheumatology 2009, 5:130-131.
16. Isomäki P., Punnonen J. Pro- and anti-inflammatory cytokines in rheumatoid arthritis. Annals of Medicine 1997, 29:499-507.
17. Jorgensen C., Apparailly F. Prospects for gene therapy in inflammatory arthritis. Best Practice and Research. Clinical Rheumatology 2010, 24:541-552.
18. Kelchtermans H., et al. How interferon-γ keeps autoimmune diseases in check. Trends in Immunology 2008, 29:479-486.
19. Kyburz D., Corr M. The KRN mouse model of inflammatory arthritis. Immunopathology 2003, 25:79-90.
20. Lubberts E., et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. Journal of Clinical Investigation 2000, 105:1697-1710.
21. Matsubara S., et al. Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyper-responsiveness. American Journal of Respiratory and Critical Care Medicine 2006, 173:53-63.
22. Monach P.A., et al. The role of antibodies in mouse models of rheumatoid arthritis and relevance to human disease. Advances in Immunology 2004, 82:217-248.
23. Murphy D.M., O'Byrne P.M. Recent advances in the pathophysiology of asthma. Chest 2010, 137:1417-1426.
24. Neuratha M.F., Finottob S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine and Growth Factor Reviews 2011, 22:83-89.
25. Nigrovic P.A., Lee D.M. Innate immunity and immune complexes in rheumatoid arthritis. Rheumatoid Arthritis 2006, 35-156. Oxford University Press, New York, NY. G.S. Firestein, G. Panayi, F. Wollheim (Eds.).
26. Pine P.R., et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clinical Immunology 2007, 124:244-257.
27. Riccaboni M., et al. Spleen tyrosine kinases: biology, therapeutic targets and drugs. Drug Discovery Today 2010, 15517-15530.
28. Rivera J., Colbert R.A. Healing the Syk through kinase inhibitors. New England Journal of Medicine 2010, 363:1362-1364. (Comment on Weinblatt M.E. et al., 2010).
29. Sanderson M.P., et al. Syk: a novel target for treatment of inflammation in lung disease. Inflammation & Allergy - Drug Targets 2009, 8:87-95.
30. Sanderson M.P., et al. Comparison of the anti-allergic activity of Syk inhibitors with optimized Syk siRNAs in Fce{open}RI-activated RBL-2H3 basophilic cells. Cellular Immunology 2010, 262:28-34.
31. Sarkar S.N., Sen G.C. Novel functions of proteins encoded by viral stress-inducible genes. Pharmacology & Therapeutics 2004, 103:245-259.
32. Schett G., et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis & Rheumatism 2000, 43:2501-2512.
33. Scott L. Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis. Drugs 2011, 71:1121-1132.
34. Stenton G.R., et al. Aerosolized Syk antisense suppresses Syk expression, mediator release from macrophages, and pulmonary inflammation. Journal of Immunology 2000, 164:3790-3797.
35. Stenton G.R., et al. Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase. Journal of Immunology 2002, 169:1028-1036.
36. Sweeney S.E., Firestein G.S. Mitogen activated protein kinase inhibitors: where are we now and where are we going?. Annals of the Rheumatic Diseases 2006, 65(Suppl. 3):iii83-iii88.
37. Thalhamer T., et al. MAPKs and their relevance to arthritis and inflammation. Rheumatology 2008, 47:409-414.
38. Thiel M.J., et al. Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis. Arthritis and Rheumatism 2007, 56:3347-3357.
39. Thompson J.D. Applications of antisense and siRNAs during preclinical drug development. Drug Discovery Today 2002, 17:912-917.
40. Tsuboi N., et al. Regulation of human neutrophil Fcγ receptor IIa by C5a receptor promotes inflammatory arthritis in mice. Arthritis and Rheumatism 2011, 63:467-478.
41. Turner M., et al. Tyrosine kinase SYK: essential functions for immunoreceptor signaling. Immunology Today 2000, 21:148-154.
42. Ulanova M., et al. Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis. Expert Opinion on Therapeutic Targets 2005, 9:901-921.
43. Ulanova M., et al. Syk tyrosine kinase participates in beta1-integrin signaling and inflammatory responses in airway epithelial cells. American Journal of Physiology - Lung Cellular and Molecular Physiology 2005, 288:L497-L507.
44. Ulanova M., et al. Involvement of Syk kinase in TNF-induced nitric oxide production by airway epithelial cells. Biochemical and Biophysical Research Communications 2006, 351:431-437.
45. Weinblatt M.E., et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis and Rheumatism 2008, 58:3309-3318.
46. Weinblatt M.E., et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. New England Journal of Medicine 2010, 363:1303-1312.
47. Weiss W.A., et al. Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nature Chemical Biology 2007, 3:739-744.
48. Woodrick R., Ruderman E.M. Anti-interleukin-6 therapy in rheumatoid arthritis. Bulletin of the NYU Hospital for Joint Diseases 2010, 68:211-217.
49. Woods J.M., et al. IL-4 adenoviral gene therapy reduces inflammation, proinflammatory cytokines, vascularization and bony destruction in rat adjuvant-induced arthritis. Journal of Immunology 2001, 166:1214-1222.
50. Yamada T., et al. IL-1 induced chemokine production through the association of Syk with TNF receptor-associated factor-6 in nasal fibroblast lines. Journal of Immunology 2001, 167:283-288.
51. Zimmermann N., et al. Chemokines in asthma: cooperative interaction between chemokines and IL-13. Journal of Allergy and Clinical Immunology 2003, 111:227-242.